Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
Hair loss treatments discussed include dermarolling, minoxidil, finasteride, and RU58841. Some users find dermarolling sad, while others mention the complexity of biological systems and limited research funding for hair loss.
Hair regrowth treatment involving 3aHSD enzyme shows 6% improvement in 18 weeks. Sulforaphane, L-Menthol, and Dexpanthenol are potential ingredients for new hair loss solution.
The conversation discusses the tension theory as a cause of male pattern baldness (MPB), suggesting that scalp tension and reduced subcutaneous fat layer contribute to hair loss. Treatments mentioned include Minoxidil, finasteride, microneedling, scalp massages, and Botox.
High cost of studying 3α-Hydroxysteroid dehydrogenase in hair loss led to suggestions of crowdfunding for research. Users discussed using Procyanidin B2/melatonin topical treatment and tracking funds with blockchain.
The conversation discusses an 8.5-month progress of using Minoxidil, Finasteride, and RU58841 for hair loss. People are complimenting the user on the significant improvement in hair thickness.
Treatments for hair loss, focusing on Fluridil/Topilutamide (Eucapil), Finasteride and RU58841 (Alfatradiol). The user reported that the Fluridil seemed to work well but had side effects of testicle ache, decreased mood and sex drive.
Hair loss treatments, including Dutasteride 0.5mg daily, finasteride 1mg daily, minoxidil 5% 2x daily, dermarolling, low-level light therapy (LLLT), ketokonazole shampoo, and diet optimization; discussing their effectiveness and side effects.
The conversation discusses how applying topical tretinoin for 5 days can convert 43% of individuals who initially do not respond to minoxidil into responders, enhancing the effect of minoxidil on hair growth. Specific treatments mentioned are minoxidil and tretinoin.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
A 33-year-old man is concerned about potential hair loss, comparing his hairline to his father's and noticing increased shedding and thinning. He is considering treatments like Minoxidil and Finasteride but is unsure if he has male pattern baldness.
The conversation suggests that people should consult a dermatologist to understand their type of hair loss before starting treatments like finasteride or dutasteride, especially if they have autoimmune issues or low DHT. Some participants believe in starting treatment like finasteride immediately if hair loss is due to DHT, while others recommend ruling out other causes and considering minoxidil first, especially for younger individuals.
A user's experience with hair loss treatments, including Finasteride, Minoxidil, Nizoral Shampoo, Rosemary Oil, Vitamin D, Biotin, Vitamin C, Zinc and Dermarolling, that have not been successful over the past 14 months. Other users gave advice on how to cope with the issue, such as exercising, changing mindset, and shaving their head.
The conversation discusses whether dutasteride might cause less depression than finasteride for hair loss treatment, with some users suggesting it could due to different mechanisms of action or molecular size, while others express skepticism or share personal experiences with these medications.
The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.
The conversation discusses verteporfin as a potential treatment for hair regeneration, which could lead to unlimited hair transplants by healing the donor area. Some users are considering using verteporfin now, while others are hopeful it will be available for future hair transplants.
The conversation is about experiences with Kintor's KX-826 for hair loss, specifically regarding side effects. Some users reported side effects from grey market versions, questioning their authenticity.
The user is frustrated with the delayed delivery of their Pryiltamide order from Koshine. They mention the order was shipped on August 23 but have received no updates since.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
The conversation is about the delay in receiving updates on the HMI-115 phase 1 trial for hair loss. No specific treatments are mentioned in the conversation.
Dutasteride might be better for hairline due to varying levels of 5AR activity in scalps. Genetic tests can determine if finasteride is enough or if dutasteride is needed.
The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.
The conversation concludes that finasteride, a 5α-Reductase inhibitor used for hair loss, does not impair cognition either short-term or long-term. It suggests "brain fog" is not caused by the medication.